Share Email Print

Journal of Biomedical Optics

Near-infrared narrow-band imaging of gold/silica nanoshells in tumors
Author(s): Priyaveena Puvanakrishnan; Jaesook Park; Parameshwaran Diagaradjane; Jon A. Schwartz; Christopher L. Coleman; Kelly L. Gill-Sharp; Kristina L. Sang; J. Donald Payne; Sunil Krishnan; James W. Tunnell
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Gold nanoshells (GNS) are a new class of nanoparticles that can be optically tuned to scatter or absorb light from the near-ultraviolet to near-infrared (NIR) region by varying the core (dielectric silica)/shell (gold) ratio. In addition to spectral tunability, GNS are inert and bioconjugatable, making them potential labels for in vivo imaging and therapy of tumors. We report the use of GNS as exogenous contrast agents for enhanced visualization of tumors using narrow-band imaging (NBI). NBI takes advantage of the strong NIR absorption of GNS to distinguish between blood and nanoshells in the tumor by imaging in narrow wavelength bands in the visible and NIR, respectively. Using tissue-simulating phantoms, we determined the optimum wavelengths to enhance contrast between blood and GNS. We then used the optimum wavelengths for ex vivo imaging of tumors extracted from human colon cancer xenograft bearing mice injected with GNS. Systemically delivered GNS accumulated passively in tumor xenografts by the enhanced permeability and retention (EPR) effect. Ex vivo NBI of tumor xenografts demonstrated heterogeneous distribution of GNS with a clear distinction from the tumor vasculature. The results of this study demonstrate the feasibility of using GNS as contrast agents to visualize tumors using NBI.

Paper Details

Date Published: 1 March 2009
PDF: 6 pages
J. Biomed. Opt. 14(2) 024044 doi: 10.1117/1.3120494
Published in: Journal of Biomedical Optics Volume 14, Issue 2
Show Author Affiliations
Priyaveena Puvanakrishnan, The Univ. of Texas at Austin (United States)
Jaesook Park, The Univ. of Texas at Austin (United States)
Parameshwaran Diagaradjane, The Univ. of Texas M.D. Anderson Cancer Ctr. (United States)
Jon A. Schwartz, Nanospectra Biosciences, Inc. (United States)
Christopher L. Coleman, Agilent Technologies, Inc. (United States)
Kelly L. Gill-Sharp, Nanospectra Biosciences, Inc. (United States)
Kristina L. Sang, Nanospectra Biosciences, Inc. (United States)
J. Donald Payne, Nanospectra Biosciences, Inc. (United States)
Sunil Krishnan, The Univ. of Texas M.D. Anderson Cancer Ctr. (United States)
James W. Tunnell, The Univ. of Texas at Austin (United States)

© SPIE. Terms of Use
Back to Top